data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Cabaletta Bio
(NASDAQ:CABA)
1.01
-0.05[-4.72%]
At close: Jun 24
1.0016
-0.0084[-0.83%]
After Hours: 4:46PM EDT
Day High/Low0.99 - 1.15
52 Week High/Low0.9 - 14.95
Open / Close1.09 / 1.01
Float / Outstanding27.5M / 29M
Vol / Avg.230.1K / 151.1K
Mkt Cap29.3M
P/E-
50d Avg. Price1.34
Div / Yield-
Payout Ratio-
EPS-0.45
Total Float27.5M

Cabaletta Bio (NASDAQ:CABA), Quotes and News Summary

Cabaletta Bio (NASDAQ: CABA)

Day High/Low0.99 - 1.15
52 Week High/Low0.9 - 14.95
Open / Close1.09 / 1.01
Float / Outstanding27.5M / 29M
Vol / Avg.230.1K / 151.1K
Mkt Cap29.3M
P/E-
50d Avg. Price1.34
Div / Yield-
Payout Ratio-
EPS-0.45
Total Float27.5M
Benzinga - May 25, 2022, 3:10PM
Benzinga - May 25, 2022, 7:07AM
Benzinga - May 18, 2022, 12:49PM
Benzinga - May 12, 2022, 7:19AM
Benzinga - May 2, 2022, 4:33PM
Benzinga - Mar 18, 2022, 8:29AM
Benzinga - Mar 18, 2022, 6:32AM
Benzinga - Mar 17, 2022, 7:09AM
Benzinga - Mar 1, 2022, 8:25AM
Benzinga - Dec 15, 2021, 8:56AM
load more
Sector: Health Care.Industry: Biotechnology
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAAR, T cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CAAR T cell product candidate was designed based on the clinically validated and commercially approved Chimeric Antigen Receptor, or CAR, T cell technology that is marketed for the treatment of B cell cancers.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-04
REV
Q1 2022Est.ActualSurprise
EPS-0.600-0.450 0.1500
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Cabaletta Bio Questions & Answers

Q
How do I buy Cabaletta Bio (CABA) stock?
A

You can purchase shares of Cabaletta Bio (NASDAQ: CABA) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Cabaletta Bio's (CABA) competitors?
Q
What is the target price for Cabaletta Bio (CABA) stock?
A

The latest price target for Cabaletta Bio (NASDAQ: CABA) was reported by Mizuho on Wednesday, May 25, 2022. The analyst firm set a price target for 10.00 expecting CABA to rise to within 12 months (a possible 890.10% upside). 6 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Cabaletta Bio (CABA)?
A

The stock price for Cabaletta Bio (NASDAQ: CABA) is $1.01 last updated June 24, 2022, 8:00 PM UTC.

Q
Does Cabaletta Bio (CABA) pay a dividend?
A

There are no upcoming dividends for Cabaletta Bio.

Q
When is Cabaletta Bio (NASDAQ:CABA) reporting earnings?
A

Cabaletta Bio’s Q2 earnings are confirmed for Thursday, August 4, 2022.

Q
Is Cabaletta Bio (CABA) going to split?
A

There is no upcoming split for Cabaletta Bio.

Q
What sector and industry does Cabaletta Bio (CABA) operate in?
A

Cabaletta Bio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.